scholarly article | Q13442814 |
P356 | DOI | 10.2967/JNUMED.115.154138 |
P698 | PubMed publication ID | 25883123 |
P50 | author | Matthieu Resche-Rigon | Q41907674 |
Elif Hindié | Q47460841 | ||
Dimitris Visvikis | Q91680418 | ||
P2093 | author name string | Anne de Roquancourt | |
Marc Espié | |||
Alice Sanna | |||
Patricia de Cremoux | |||
Sylvie Giacchetti | |||
Luis Teixeira | |||
David Groheux | |||
Pascal Merlet | |||
Mathieu Hatt | |||
Mohamed Majdoub | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
P304 | page(s) | 824-831 | |
P577 | publication date | 2015-04-16 | |
P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
P1476 | title | Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. | |
P478 | volume | 56 |
Q52584340 | 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. |
Q37566580 | 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis |
Q38726440 | Biomarkers of residual disease after neoadjuvant therapy for breast cancer |
Q38663416 | Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence |
Q43082312 | Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy |
Q53396296 | Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer. |
Q48047542 | Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients |
Q58775208 | Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study |
Q36403339 | Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy |
Q55505363 | FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. |
Q50172829 | Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy |
Q51727954 | Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer? |
Q90260579 | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues |
Q92807885 | Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy |
Q52895573 | The Role of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors. |
Q41491212 | Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. |
Q37582345 | ¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer |
Q38693888 | ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials |
Search more.